Clover Health Investments, Corp
Here’s whether Clover Health Investments, Corp (CLOV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+3.25% over 10 days); RSI 58 — healthy momentum range; strong 1-year return of +79.0%; 3-month momentum positive (+32.6%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 17.7% off its 52-week high. Score: +5/7.
CLOV is holding above its long-term 200-day MA ($3.05) but has slipped below the 50-day MA ($4.66), pointing to short-term weakness in an otherwise intact trend. An RSI of 57.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +79.0% compares to +20.4% for SPY (beat the market by 58.6%).